Diagnostic utility of Sudoscan for detecting bortezomib-induced painful neuropathy: a study on 18 patients with multiple myeloma

Introduction In the past few years, treatment of multiple myeloma has undergone a deep change for the employment of novel treatment comprising proteasome inhibitors. Bortezomib is a first-line drug in therapy of multiple myeloma. The onset of peripheral neuropathy is a dose-limiting collateral effect of the drug. This neuropathy is a distal symmetric neuropathy that affects both large and small fibers. Nerve conduction study (NCS) can be used for the diagnosis of bortezomib neuropathy, but this technique demonstrates alterations of the large nerve fibers. Sudoscan is a novel technique utilized to offer an evaluation of sudomotor function. The main objective of this study was to compare the sensitivity and diagnostic specificity of Sudoscan with respect to the nerve conduction study after bortezomib treatment. Material and methods A total of 18 multiple myeloma patients were studied, 10 (55.5%) men and 8 (44.5%) women. Patients were analyzed at baseline and after 6 months of treatment with bortezomib. Subjects were submitted to nerve conduction study and electrochemical skin conductance evaluation with the Sudoscan device. Patients were also submitted to a clinical measure of pain and neuropathy. Results At baseline NCS showed that only the mean sural SAP amplitude was below the 2SD lower limit of normal in 3 (16.7%) patients, while at same time we found an alteration of Sudoscan profiles in 2 (11.1%) patients. After 6 months of treatment, the NCS profiles were altered in 13 (72.2%) patients, and the Sudoscan profiles were modified in 11 (61.1%) subjects. Conclusions Our results suggest that Sudoscan can be considered for the diagnosis of bortezomib-induced neuropathy. It is objective, reproducible, and surely easier than the traditional nerve conduction study. Sudoscan may be a useful help to manage the therapeutic interventions in multiple myeloma.

[1]  C. Vollono,et al.  Small fibre neuropathy in mitochondrial diseases explored with sudoscan , 2018, Clinical Neurophysiology.

[2]  J. Lefaucheur,et al.  The value of electrochemical skin conductance measurement using Sudoscan® in the assessment of patients with familial amyloid polyneuropathy , 2018, Clinical Neurophysiology.

[3]  Lingxiu Zhang,et al.  Down-regulation of miR-203a by lncRNA PVT1 in multiple myeloma promotes cell proliferation , 2018, Archives of medical science : AMS.

[4]  A. Allegra,et al.  Immunoproteasome‐selective and non‐selective inhibitors: A promising approach for the treatment of multiple myeloma , 2017, Pharmacology & therapeutics.

[5]  L. Stitt,et al.  Sensitivity of the DN4 in Screening for Neuropathic Pain Syndromes , 2017, The Clinical journal of pain.

[6]  H. Goldschmidt,et al.  Genetic Susceptibility to Bortezomib-Induced Peripheral Neuroropathy: Replication of the Reported Candidate Susceptibility Loci , 2017, Neurochemical Research.

[7]  D. Gudbjartsson,et al.  Genome-wide association study identifies multiple susceptibility loci for multiple myeloma , 2016, Nature Communications.

[8]  J. Calvet,et al.  Quick, non-invasive and quantitative assessment of small fiber neuropathy in patients receiving chemotherapy , 2016, Journal of Neuro-Oncology.

[9]  I. Wilkinson,et al.  SUDOSCAN: A Simple, Rapid, and Objective Method with Potential for Screening for Diabetic Peripheral Neuropathy , 2015, PloS one.

[10]  A. Vinik,et al.  The New Age of Sudomotor Function Testing: A Sensitive and Specific Biomarker for Diagnosis, Estimation of Severity, Monitoring Progression, and Regression in Response to Intervention , 2015, Front. Endocrinol..

[11]  M. Zhan,et al.  Clinical neuropathy scales in neuropathy associated with impaired glucose tolerance. , 2015, Journal of diabetes and its complications.

[12]  Gillian L. Currie,et al.  Incidence, prevalence, and predictors of chemotherapy-induced peripheral neuropathy: A systematic review and meta-analysis , 2014, PAIN®.

[13]  J. Hoseki,et al.  Mitochondrial impairment triggers cytosolic oxidative stress and cell death following proteasome inhibition , 2014, Scientific Reports.

[14]  P. Dougherty,et al.  Altered discharges of spinal neurons parallel the behavioral phenotype shown by rats with bortezomib related chemotherapy induced peripheral neuropathy , 2014, Brain Research.

[15]  Sandra P. Reyna,et al.  The diagnostic utility of Sudoscan for distal symmetric peripheral neuropathy. , 2014, Journal of diabetes and its complications.

[16]  D. Ziegler,et al.  New vistas in the diagnosis of diabetic polyneuropathy , 2014, Endocrine.

[17]  N. Staff,et al.  Bortezomib alters microtubule polymerization and axonal transport in rat dorsal root ganglion neurons. , 2013, Neurotoxicology.

[18]  A. Vinik,et al.  Sudoscan, a noninvasive tool for detecting diabetic small fiber neuropathy and autonomic dysfunction. , 2013, Diabetes technology & therapeutics.

[19]  S. Vincent Rajkumar,et al.  Continued improvement in survival in multiple myeloma: changes in early mortality and outcomes in older patients , 2013, Leukemia.

[20]  Thomas W. Mühleisen,et al.  Common variation at 3q26.2, 6p21.33, 17p11.2 and 22q13.1 influences multiple myeloma risk , 2013, Nature Genetics.

[21]  A. Allegra,et al.  Monoclonal antibodies: potential new therapeutic treatment against multiple myeloma , 2013, European journal of haematology.

[22]  J. Laubach,et al.  Peripheral neuropathy in multiple myeloma patients receiving lenalidomide, bortezomib, and dexamethasone (RVD) therapy. , 2013, Blood.

[23]  J. Calvet,et al.  Screening of cardiovascular autonomic neuropathy in patients with diabetes using non-invasive quick and simple assessment of sudomotor function. , 2012, Diabetes & metabolism.

[24]  A. Allegra,et al.  Increase of novel biomarkers for oxidative stress in patients with plasma cell disorders and in multiple myeloma patients with bone lesions , 2012, Inflammation Research.

[25]  H. Gin,et al.  Non-invasive and quantitative assessment of sudomotor function for peripheral diabetic neuropathy evaluation. , 2011, Diabetes & metabolism.

[26]  R. Freeman,et al.  Cardiovascular autonomic neuropathy in diabetes: clinical impact, assessment, diagnosis, and management , 2011, Diabetes/metabolism research and reviews.

[27]  P. Dougherty,et al.  Follow-up psychophysical studies in bortezomib-related chemoneuropathy patients. , 2011, The journal of pain : official journal of the American Pain Society.

[28]  Jun Shi,et al.  Polymorphisms of nuclear factor-κB family genes are associated with development of multiple myeloma and treatment outcome in patients receiving bortezomib-based regimens , 2011, Haematologica.

[29]  A. Allegra,et al.  Novel therapeutic strategies in multiple myeloma: role of the heat shock protein inhibitors , 2011, European journal of haematology.

[30]  B. Bauduceau,et al.  A new simple method for assessing sudomotor function: relevance in type 2 diabetes. , 2010, Diabetes & metabolism.

[31]  Heinz Ludwig,et al.  Treatment-related peripheral neuropathy in multiple myeloma: the challenge continues. , 2010, The Lancet. Oncology.

[32]  W. Litchy,et al.  Signs and symptoms versus nerve conduction studies to diagnose diabetic sensorimotor polyneuropathy: Cl vs. NPhys trial , 2010, Muscle & nerve.

[33]  A. Jakubowiak,et al.  Peripheral neuropathy during bortezomib treatment of multiple myeloma: a review of recent studies , 2010, Leukemia & lymphoma.

[34]  D. Esseltine,et al.  Reversibility of symptomatic peripheral neuropathy with bortezomib in the phase III APEX trial in relapsed multiple myeloma: impact of a dose‐modification guideline , 2009, British journal of haematology.

[35]  P. Brunswick,et al.  Use of Ni electrodes chronoamperometry for improved diagnostics of diabetes and cardiac diseases , 2007, 2007 29th Annual International Conference of the IEEE Engineering in Medicine and Biology Society.

[36]  G. Cavaletti,et al.  Bortezomib-induced peripheral neurotoxicity: still far from a painless gain , 2007, Haematologica.

[37]  A. Rapoport,et al.  Neurotoxicity of bortezomib therapy in multiple myeloma: A single‐center experience and review of the literature , 2007, Cancer.

[38]  R. Orlowski,et al.  The proteasome and proteasome inhibitors in cancer therapy. , 2006, Annual review of pharmacology and toxicology.

[39]  Peter J Dyck,et al.  Monotonicity of nerve tests in diabetes: subclinical nerve dysfunction precedes diagnosis of polyneuropathy. , 2005, Diabetes care.

[40]  B. Hoggart,et al.  Pain: a review of three commonly used pain rating scales. , 2005, Journal of clinical nursing.

[41]  Kevin D. Nullmeyer,et al.  Mitochondrial-mediated disregulation of Ca2+ is a critical determinant of Velcade (PS-341/bortezomib) cytotoxicity in myeloma cell lines. , 2005, Cancer research.

[42]  G. Gronseth,et al.  Distal symmetric polyneuropathy: A definition for clinical research , 2005, Neurology.

[43]  R. Malik,et al.  Small Fiber Neuropathy in Diabetes: Clinical Consequence and Assessment , 2004, The international journal of lower extremity wounds.

[44]  B. Zinman,et al.  Simple screening tests for peripheral neuropathy in the diabetes clinic. , 2000, Diabetes care.

[45]  F. Weber,et al.  Electrodiagnostic examination of lumbosacral radiculopathies. , 2000, Electromyography and clinical neurophysiology.

[46]  J. McArthur,et al.  Epidermal nerve fiber density: normative reference range and diagnostic efficiency. , 1998, Archives of neurology.

[47]  R O Potts,et al.  Electrical properties of skin at moderate voltages: contribution of appendageal macropores. , 1998, Biophysical journal.

[48]  P. Low,et al.  Thermoregulatory sweating abnormalities in diabetes mellitus. , 1989, Mayo Clinic proceedings.

[49]  Sabina Russo,et al.  New orally active proteasome inhibitors in multiple myeloma. , 2014, Leukemia research.